JPMorgan analyst Christopher Schott downgraded Pfizer to Neutral with an unchanged price target of $46. The shares closed yesterday up 48c to $44.40. The analyst cites valuation for his move to the sidelines after a “strong” 2018 which has to the stock up over 20% year-to-date. Further, he believes Pfizer’s product pipeline needs to expand following the patent expiration of Lyrica in 2019.
https://thefly.com/landingPageNews.php?id=2835009
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.